Merck said on Wednesday it will acquire UK-based Verona Pharma for about $10 billion, gaining a promising respiratory ...

Health-care companies rose as deal activity offset more health-insurance controversy. Merck struck a roughly $10 billion deal to buy Verona Pharma, bolstering its lineup with the chronic obstructive ...

Merck (MRK) is spending about $10 billion to acquire Verona Pharma (VRNA) as the company looks to fill future revenue gaps.

Merck is looking to strengthen its respiratory treatments as part of efforts to reduce dependence on its blockbuster cancer ...

Globally, $105.3 billion worth of pharmaceuticals and biotech M&A deals have been inked so far in 2025, according to data ...

Merck is acquiring UK-based Verona Pharma for about $10 billion, as part of the U.S. drugmaker's strategy to diversify beyond ...

In this week’s edition of InnovationRx, we look at Immuneering’s slow-and-steady approach to cancer fighting, litigation over ...

Merck agreed to buy respiratory drugmaker Verona for about $10 billion as part of its ongoing search for ways to fill the ...

Merck & Co., Inc. is acquiring Verona Pharma plc for $10bn to bolster long-term growth with COPD drug Ohtuvayre. Click for my ...

The U.S. drug giant said that Verona’s Ohtuvayre, which treats chronic obstructive pulmonary disease, will strengthen its lineup of cardiovascular treatments.

Merck announces plans of buying Verona for a huge premium. VRNA deal could shield Merck from two major headwinds.

The move bolsters Merck's lineup as it braces for the 2028 loss of patent exclusivity for blockbuster cancer drug Keytruda.